

# Cairn Therapeutics to Present at MedInvest Biotech & Pharma Investor Conference

---

WILMINGTON, DE, USA, March 28, 2024 /EINPresswire.com/ -- Cairn Therapeutics, Inc., ("Cairn" or the "Company"), a pharmaceutical company developing highly targeted medications for the treatment of cancer, today announced that it will present an update on the company's flagship product, CT-262, at the MedInvest Biotech & Pharma Investor Conference. Cairn's CEO, W. Scott Evangelista and COO, Tom Fritz, will present and host one-on-one meetings at the conference being held at the Cooley offices in New York City on April 3-4, 2024. For more information about the conference, see [here](#).

## About Cairn Therapeutics

Cairn Therapeutics, Inc. is a pharmaceutical company with a mission to help patients beat cancer. Founded in 2016, Cairn is developing its lead candidate, CT-262, a first-in-its-class treatment for solid and hematological tumors. Cairn holds the exclusive worldwide license to CT-262, which was invented at Scripps Research Institute using unique medicinal chemistry to create a highly potent DNA alkylating agent that preferentially activates in cancer cells. In vitro and in vivo animal oncology studies have shown CT-262 to produce markedly better efficacy and safety results compared to current first-line therapies in these nonclinical models, and highlight the potential to replace these compounds in a broad array of cancers. Cairn intends to file an IND and begin First-in-Human trials this year. For more information, visit [www.cairntherapeutics.com](http://www.cairntherapeutics.com).

Sutton Faller

Cairn Therapeutics, Inc.

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/699538276>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.